Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma


About this study

This phase II trial evaluates how well AVD (doxorubicin hydrochloride, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma. Drugs used in the chemotherapy, such as doxorubicin hydrochloride, vinblastine, dacarbazine, and brentuximab vedotin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, and/or by stopping them from spreading. Targeted agent, such as nivolumab, may interfere with the ability of cancer cells to grow and spread by enhancing the immune system. Giving doxorubicin hydrochloride, vinblastine, dacarbazine, brentuximab vedotin, and nivolumab may improve survival of patients with stage I-II Hodgkin lymphoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria - Registration:

  • Age ≥18 years and ≤ 60 years of age.
  • Measurable disease (≥ 1.5 cm) as assessed by 2 dimensional measurement by CT.
  • Previously untreated stage I or II non-bulky (defined as a mass measuring < 10 cm in the longest dimension by CT) Classical Hodgkin lymphoma.
  • ECOG Performance Status (PS) 0-2. (Form is available on the ACCRU web site
  • Life expectancy ≥3 months.
  • Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C ≤1 year prior to registration.
  • Adequate bone marrow function (without transfusion support >7 days prior to registration) function as demonstrated by:
    • White blood cell ≥ 2,000 /mm3;
    • Hemoglobin ≥ 8.5 g/dL;
    • Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3;
    • Platelet count ≥ 75,000/mm3.
  • Adequate hepatic and renal function obtained ≤14 days prior to registration as demonstrated by:
    • Alanine and Aspartate aminotransferase (ALT/AST) ≤ 2.5 ラ upper limit of normal (ULN);
    • Total serum bilirubin ≤ 1.5 ラ ULN (if documented Gilberts syndrome ≤ 3 x ULN);
    • Serum creatinine ≤ 1.5 × ULN or measured calculated creatinine clearance ≥ 40 ml/min for subject with creatinine levels > 1.5 x institutional ULN (per Cockcroft-Gault formula below; see Appendix III - Renal Impairment Guidelines).
  • Cockcroft-Gault Equation:
    • Creatinine clearance for males = (140 - age)(weight in kg) | (72)(serum creatinine in mg/dL).
    • Creatinine clearance for females = (140 - age)(weight in kg)(0.85) | (72)(serum creatinine in mg/dL) .
  • Negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to registration in women of child-bearing potential (WOCBP).
  • Sexually active female of reproductive capability ie, WOCBP, has agreed to use a medically accepted form of contraception from time of registration to completion of study therapy through 24 weeks (6 months) after last dose of NVB or BV.
    • Note: Females of non-child-bearing potential are those who are postmenopausal for > 1 year or who have had a bilateral tubal ligation or hysterectomy. 
  • Male subjects agree to use an adequate method of contraception starting with the first dose of study therapy through 31 weeks after the last dose of study therapy.
  • Provide informed written consent.
  • Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
    • Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up.

Exclusion Criteria - Registration:


  • Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
    • Pregnant women;
    • Nursing women;
    • Men or women of childbearing potential who are unwilling to employ adequate contraception.
  • Prior therapies including involved field radiation therapy.
  • Bulky disease (defined as a nodal mass measuring ≥ 10 cm by CT).
  • Known CNS involvement.
  • Moderate or severe hepatic insufficiency Child-Pugh score >6 (see Appendix IV - Child- Pugh Hepatic Impairment Score).
  • Severe renal impairment (i.e., creatinine clearance < 40 mL/min).
  • Symptomatic cardiac disease including ventricular dysfunction, left ventricular ejection fraction < 45%, symptomatic coronary artery disease or symptomatic arrhythmias.
  • Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy ≤ 7 days prior to registration.
  • Known history of active TB (Bacillus Tuberculosis).
  • Requires therapy with agents that have a predisposition for hepatoxicity.
  • Hypersensitivity to NVB or any of its excipients or to any component of AVD + BV therapy.
  • Requires immunosuppressive doses of corticosteroid therapy (>10 mg/day prednisone equivalents) for ≥ 2 weeks prior to registration.
  • Active, known, or suspected autoimmune disease that requires systemic weeks prior to registration.
  • Active, known, or suspected autoimmune disease that requires systemic treatment (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
    • Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
  • Active infection requiring systemic IV antibiotic therapy.
  • History of Steven’s Johnson’s syndrome, toxic epidermal necrolysis syndrome (TENs) or motor neuropathy.
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
  • Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  • Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
  • Received a live vaccine ≤30 days prior to registration.
    • Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed. Routine vaccinations, including seasonal influenza, must be given ≥ 2 weeks prior to registration.
  • History of allergies and adverse drug reaction to study drug components.
  • History of another primary malignancy that has not been in remission for at least 3 years.
    • Note: The following are exempt for the 3-year limit: nonmelanoma skin cancer, fully excised melanoma in situ [Stage 0], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear.
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
  • History of progressive PML, known history of pancreatitis, active grade 3 or higher viral, bacterial or fungal infection ≤ 2 weeks prior to registration and documented history of cerebrovascular event (stroke or TIA) ≤6 months prior to registration.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Stephen Ansell, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions